Issues regarding growth hormone replacement in growth hormone deficient adults.

Abstract

Australian and New Zealand Journal of MedicineVolume 29, Issue 3 p. 289-291 Free Access Issues regarding growth hormone replacement in growth hormone deficient adults ROSS C. CUNEO, ROSS C. CUNEO Associate Professor of Medicine, Metabolic Research Unit, University of Queensland, Department of Medicine, Princess Alexandra Hospital, Brisbane, Qld.Search for more papers by this author ROSS C. CUNEO, ROSS C. CUNEO Associate Professor of Medicine, Metabolic Research Unit, University of Queensland, Department of Medicine, Princess Alexandra Hospital, Brisbane, Qld.Search for more papers by this author First published: 25 March 2008 https://doi.org/10.1111/j.1445-5994.1999.tb00707.xCitations: 2AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References 1 Cuneo RC, Salomon F, McGauley GA, Sönksen PH. The growth hormone deficiency syndrome in adults. Clin Endocrinol 1992; 37: 387– 97. 2 Carroll PV, Christ ER, Bengtsson B et al. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. J Clin Endocrinol Metab 1998; 83: 382– 95. 3 Hoffman DM, Ho KKY. Growth hormone deficiency in adults: to treat or not to treat. Aust NZ J Med 1999; 29: 342– 9. 4 Rosen T, Bengtsson B. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990; 336: 285– 8. 5 Bulow B, Hagmar L, Mikoczy Z, Nordstrom CH, Erfurth EM. Increased cerebrovascular mortality in patients with hypopituitarism. Clin Endocrinol 1997; 46: 75– 81. 6 Cuneo RC. Efficacy of growth hormone replacement therapy: lipid and cardiovascular effects. Endocrinologist 1998; 8: 22S– 30S. 7 Gibney J, Wallace J, Spinks T, Schnorr L, Ranicar A, Cuneo R, Lockhart S, Burnand K, Salomon F, Sonksen P, Russell-Jones D. The effects of 10 years of recombinant human growth hormone in adult growth hormone deficient patients. J Clin Endocrinol Metab (in press) August 1999. 8 Cuneo RC, Judd S, Wallace JD et al. The Australian multicenter trial of growth hormone (GH) treatment in GH-deficient adults. J Clin Endocrinol Metab 1998; 83: 107– 16. 9 Cuneo RC, Salomon F, Wiles CM, Hesp R, Sönksen PH. Growth hormone treatment in growth hormone-deficient adults. 1. Effects on muscle mass and strength. J Appl Physiol 1991; 70: 688– 94. 10 Cuneo RC, Salomon F, Wiles CM, Hesp R, Sönksen PH. Growth hormone treatment in growth hormone-deficient adults. II. Effects on exercise performance. J Appl Physiol 1991; 70: 695– 700. 11 Johannsson G, Bjarnason R, Bramnert M et al. The individual responsiveness to growth hormone (GH) treatment in GH-deficient adults is dependent on the level of GH-binding protein, body mass index, age, and gender. J Clin Endocrinol Metab 1996; 81: 1575– 81. 12 Attanasio AF, Lamberts SW, Matranga AM et al. Adult growth hormone (GH)-deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment. Adult Growth Hormone Deficiency Study Group. J Clin Endocrinol Metab 1997; 82: 82– 8. 13 Rosenfeld RG. Is growth hormone deficiency a viable diagnosis? [editorial; comment]. J Clin Endocrinol Metab 1997; 82: 349– 51. 14 Growth Hormone Research Society. Invited report of a workshop: consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the growth hormone research society workshop on adult growth hormone deficiency. J Clin Endocrinol Metab 1998; 83: 379– 81. 15 Holmes SJ, Shalet SM. Which adults develop side-effects of growth hormone replacement Clin Endocrinol 1995; 43: 143– 9. 16 Orme SM, McNally RJ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 1998; 83: 2730– 4. 17 De Boer H, Blok GJ, Voerman B, de Vries P, Popp Snijders C, van der Veen E. The optimal growth hormone replacement dose in adults, derived from bioimpedance analysis. J Clin Endocrinol Metab 1995; 80: 2069– 76. Citing Literature Volume29, Issue3June 1999Pages 289-291 ReferencesRelatedInformation